# Dalbavancin in Real Clinical Practice in Spain

> **NCT04485676** · — · COMPLETED · sponsor: **Angelini Farmacéutica** · enrollment: 187 (actual)

## Conditions studied

- Skin Diseases, Bacterial
- Skin Diseases, Infectious

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04485676
- **Lead sponsor:** Angelini Farmacéutica
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-15
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-02-21
- **Target enrollment:** 187 (ACTUAL)
- **Last updated:** 2022-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04485676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04485676, "Dalbavancin in Real Clinical Practice in Spain". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04485676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*